Effects of a new pteridine derivative on urinary sodium, potassium and magnesium excretion in conscious saline-loaded rats.
1. Two recently synthesized pteridine derivatives (RPH 3036; RPH 3038) were tested in conscious saline-loaded rats and showed natriuretic and antimagnesiuretic properties but hardly reduced potassium excretion. 2. In the same model a dose-response curve was performed for RPH 3036. ED50 and Emax values were calculated for the natriuretic (ED50 = 13.4 mumol kg-1; Emax = 1.08 mmol kg-1) and antimagnesiuretic (ED50 = 11.3 mumol kg-1; Emax = -0.099 mmol kg-1) properties of RPH 3036. There were no significant changes of potassium and calcium excretion. 3. After a single dose of RPH 3036 (100 mumol kg-1) the time course of electrolyte excretion was analysed over 6 h. RPH 3036 did not show any significant effects on renal potassium and calcium excretion whereas a pronounced decrease (P less than 0.01) in renal magnesium excretion was evident during the 6 h. A moderate increase of sodium excretion was observed only after 3, 5 and 6 h. 4. A selective reduction of magnesium secretion in the late distal tubule and collecting duct was proposed as a possible mechanism of action of RPH 3036. This would explain the fast onset of action as well as the lack of antikaliuretic and anticalciuretic effects. The high selectivity of RPH 3036 makes it potentially valuable for the future investigation of renal magnesium transport.
Netzer
T
T
Department of Pharmacology, University of Frankfurt, Germany.
Ullrich
F
F
Priewer
H
H
Majewski
M
M
Mutschler
E
E
D000818:Animals; D004305:Dose-Response Relationship, Drug; D008274:Magnesium / Q000652:urine*; D008297:Male; D011188:Potassium / Q000652:urine*; D051381:Rats; D011919:Rats, Inbred Strains; D012984:Software; D014223:Triamterene / Q000031:analogs & derivatives* / Q000494:pharmacology
C076247:RPH 2997; C076248:RPH 3036; C076249:RPH 3038; D008274:Magnesium; D011188:Potassium; D014223:Triamterene